reference/18235675

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18235675

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Randomized Controlled Trial
issn	1471-230X
issueIdentifier	1
pageRange	3-
publicationName	BMC Gastroenterology
startingPage	3
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_6d6ed1ab52c34e4a7c90469d4ac1ef59 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_9475376808ec3f60d732e10d16e05021
bibliographicCitation	Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, Gedulin B, van Vliet AA, Dorenbaum A, Palmer M. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. BMC Gastroenterology. 2018 Jan 05;18(1):3. doi: 10.1186/s12876-017-0736-0.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_42d69612f79a10c00b6812a4b82d4685 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c46ec30460b8d5255197949b339956e3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_90895d860d0173258a4070b36bbf37d9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_918cfe38944b6a33008beff6b2a659c2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a6d4c5eb47d0889b0cd863672e72c72d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8f56e3129634989de37663c26c818ca1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_390951098c967c48d3cc14bf92b68f2d http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3554-0184 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e7dc0742ba214795e0cc3928e62ecc33
date	2018-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1186/s12876-017-0736-0 https://pubmed.ncbi.nlm.nih.gov/PMC5756385 https://pubmed.ncbi.nlm.nih.gov/29304731
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21974 https://portal.issn.org/resource/ISSN/1471-230X
language	English
source	https://scigraph.springernature.com/ https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial
discusses	http://id.nlm.nih.gov/mesh/M000644160 http://id.nlm.nih.gov/mesh/M0195059 http://id.nlm.nih.gov/mesh/M0013336 http://id.nlm.nih.gov/mesh/M0381333 http://id.nlm.nih.gov/mesh/M0043344 http://id.nlm.nih.gov/mesh/M0002372 http://id.nlm.nih.gov/mesh/M0009500 http://id.nlm.nih.gov/mesh/M0384546 http://id.nlm.nih.gov/mesh/M0002475 http://id.nlm.nih.gov/mesh/M0004267 http://id.nlm.nih.gov/mesh/M0002696
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8e71fecf704632a864f016697b557ee3 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7708 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID89522394 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123743 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7444 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5997 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24987688

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID6555 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID347829333

Total number of triples: 49.